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A new theory of grippe pathogenesis with the use of proteinase-inhibitory system has been offered. It has been 
established that purification and concentration of grippe viruses by different methods did not release the virus from 
the cellular enzymes. When the experimental animals have been infected with grippe virus, we have observed 
misbalance in enzyme-inhibitory balance took place, especially during first hours after infection. Six isoforms of 
trypsin-like proteinases were obtained from the lungs of healthy mice. Antiproteinase immune sera have been 
isolated from these 6 isoforms which served to treat the experimental animals. It was antiserum to the third isoform 
that has prevented the experimental animals mortality. From the industrial wastes of gamma-globin manufacture 
the inhibitors of protein-like proteinases have been extracted which prevented the white mice’s mortality in 80% of 
cases. Endogenous inhibitors of human blood proteinases are prospective in producing anti-influenza drugs for 
humans. 
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Introduction 
 
  
  In the pathogenesis of viral diseases the interaction of 
virus with the cell has not been sufficiently studied. The 
main point here is the virus intervention into a healthy cell 
with a mandatory deproteinization of the virus. However, 
deproteinization of viruses is still poorly understood. This 
firstly refers to the mechanism of influenza virus 
introducing into cells of mammals, including humans. In 
this regard, in 1983 we proposed a new theory of influenza 
pathogenesis with proteinase-inhibitory system 
participation [1, 2].  
   The difficulties in creating products with selective 
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antiviral action are connected with biology of viral diseases 
pathogens. Recent achievements of biochemistry and 
molecular biology, revealing the features of virus 
reproduction, help to create new generations of drugs with 
directed intervention in the cycle of viral reproduction 
[3-6].  
   The purpose of the study  is to examine the state and 
role of antiproteinase systems of virus and recipient in the 
development of influenza infection to obtain and use 
fundamentally new therapeutic drugs based on inhibitors of 
trypsin-like proteases.  
   The Research objectives in this study include the 
follow six parts. The first one is to clear flu virus till 
homogenous state. The second one is to explore the nature 
of protease associated with influenza virus. The third one is 
to examine the role of proteases and their inhibitors in 
different, especially at early stages, of influenza infection 
development. The fourth one is to isolated and purified 
proteinase and its inhibitor from the lungs of healthy mice 
as well as from those infected with flu virus. The fifth one 
is to obtain specific antibodies to isoforms of trypsin-like 
proteases and study their protective effect under the  
conditionts of experimental  influenza. The last one is to 
study the protective effect of cellular inhibitors on infection 
of animals with a lethal dose of influenza virus.  
 
 
Materials and Methods 
 
Materials  
   Strains of influenza virus: A/PR/8/34 (H1N1), 
A/Aichi/2/68 (H3N2), A/USSR/90/77 (H1N1), A (Extra 
X-31), A/WSN/33 (H1N1), A/Phil/2/82 (H3N2), AO/32 
(NON1) grown on a 9-day chicken embryos, B strain 
PR-109, obtained by recombination of viruses V/Lee/40 
and B / USSR / 100/83, and MDCK cells were obtained at 
the I.D. Ivanovsky Research Institute of Virology, 
Academy of Medical Sciences of Russia and strain AO/32 
(HON1) - from the Influenza Research Institute of St. 
Petersburg, Russia. The other materials used in this work 
include 2358 items of white mice, line BALB/c and 
hybrids; 3052 pcs of chicken embryos; 1612 tubes of 
passaged MDCK cell culture;140 items of white rats, 
Wistar line.The virological, biochemical, immunological, 
molecular biological, radioisotopic techniques were used in 
this study. 
  
Proteolytic activity detection 
      To study the nature of  proteolytic activity associated 
with influenza virus we used 10-11-day chicken embryos 
and influenza virus AO/32 (HON1) with infectious titers 7 
lg EID 50 / 0,2 and HA-1: 256. The virus was accumulated 
by infecting chicken embryos in a volume of 0.2 ml, 
diluted to 10
-3
 with infectious material. Infected chicken 
embryos were incubated for 48 hours at +36 ° C. Then they 
were cooled for 18 hours at +4 ° C and then the 
virus-containing fluid was collected.  
 
Results and Discussion 
 
In the early 80's, in purifying and concentrating of 
various strains of influenza virus to produce polyvalent anti 
flu vaccines, we faced the fact that we could not release the 
influenza virus from proteolytic activity (Fig. 1) [7]. To 
resolve this problem, we have improved the methods of 
purification, but nevertheless failed to release influenza 
virus from proteolytic activity.  
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   We analysed  purified preparations of influenza 
virus for the presence of proteolytic activity and revealed 
that the treatment of influenza virus by ultracentrifugation 
techniques does not relieve flu virus from proteolytic 
activity. In saccharose gradient (15-60%) proteolytic 
activity was clearly separated into several isoforms (Tab. 1) 
[8].  
The results obtained allowed us to conclude that  flu 
virus is associated with serin-containing protease of trypsin 
–like  type of cell origin, which has molecular 
heterogeneity. Our further studies (Tab. 2) showed that all 
commercial products  contained both inhibitor, and 
trypsin-like protease, i.e. the today’s drugs are not cleared 
completely of protein impurities, or it is impossible to 
separate the viral proteins from cellular components. Viral 
proteins are tightly associated with components of the cell, 
so the structure of influenza virus should be considered 
taking into account the interaction with cellular enzymes 
and their inhibitors.  
In the body the system of proteinases and inhibitors is 
represented by a large group of proteins. Inhibitors of 
proteolytic enzymes counterbalance the corresponding 
enzymes in the body, and are in constant dynamic 
equilibrium with them [9-12]. Violation between enzymes 
and inhibitors is important for the development of 
pathological processes [13].  
Our studies show that in the lungs and blood serum of 
uninfected animals and chicken embryos, the level of 
protease activity and protease inhibiting activity  are in 
equilibrium, and the latter is violated at influenza virus A 
infection.  
    In the infectious process the most profound changes 
occur in the first hours after infection. So, in 6 hours after 
infection the number of proteinases in the lungs and serum 
of infected animals is reduced and inhibitory activity is 
increased [14]. Influenza virus infected cells induce the 
appearance of the inhibitor both in the lung tissue and 
blood serum. Consequently,  lung inhibitors are like the 
first line of an organ defense  under the action of various 
strains of influenza virus. 
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Figure 1. Scheme of purification of influenza virus. 
 
When  studying the dynamics of  proteinase and  
inhibitory activity in the chicken embryos under the 
influence of large and small infecting doses of influenza 
virus A/RR/8/34 we have found that there occurred the 
same changes as in white mice organisms (Fig. 2). During 
the period of maximal accumulation of infectious and 
hemagglutinating activity (24 hours) they did not find 
either proteinase or inhibitory activity [15].  
 Six isoforms of trypsin-like proteinase have been 
isolated from the lungs of healthy mice by while 8 isoforms 
have been isolated from the lungs of infected mice. Their 
specific proteolytic activity increased sharply compared 
with the initial material (Tab. 2). Proteinase obtained 
isoforms had a broad substrate specificity and were capable 
to hydrolyze both natural and synthetic substrates [16]. 
Antiproteinase hyperimmune rat sera have been obtained to 
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all isoforms of trypsin-like proteinases. When studying the 
protective properties of antiproteinase sera and sera of 
healthy rats on white mice infected  intarnasally with 
lethal dose of influenza virus A/PR/8/34 (IV passage), it 
was found that 100% mortality of control mice took place 
in 4-5 days (Tab. 3). The animals to which they 
administrated six times the healthy rats serum intranasally 
died on the 7th day. In the treatment of mice with the pools 
of immune sera I, II, IV, V and VI the animals mortality 
rate was reduced and lethality came much later than in the 
control group  and 20% of the animals recovered [17].  
 
Table 1 Purification of influenza virus АО/32 in succharose gradient and ultracentrifugation at 28000 min.-1, 4 h 
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1 5 0 1,6 3 0 1,5 6 0 2,6 6 0 0,58 
2 15 1:8 36 11 1:2 13,6 15 1:8 41,3 17 0 1,01 
3 32 1:16 9,6 24 1:16 8,2 23 1:16 0,45 27 0 0,37 
4 42 1:2048 33,6 24 1:16 10,2 30 1:64 0,9 29 0 0,59 
5 49 1:2048 4,4 38 1:512 25,4 37 1:512 13,8 37 0 0,80 
6 52 1:64 37 41,5 1:1024 26,2 44 1:16000 38 41 0 1,43 
7 55 1:64 37,4 46,5 1:512 12,2 47 1:16000 3,29 49 0 0,64 
8 57 1:62 6,8 53 1:16 7,9 51 1:256 0,3 53,5 0 1,28 
9       57 1:512  56 0 1,08 
Notes: * virus-containing fluid; 
** original allantoic fluid;    1 – hemagglutination reaction   
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Table 2  Purification  DEAE –cellulose-53 of  lung trypsin-like proteinase  of healthy mice 
N of fraction N of isoform Specific proteolic activity per 
mg of protein 
% of proteinase 
outcome 
% of purification 
by protein 
33 I 4,285 2,09 96,8 
53 II 83,75 5,84 99,07 
65  III 22,42 2,703 98,38 
75 IV 40,00 6,279 97,92 
121-130 V 32,6 136,74 99,98 
161-189 VI 0,787 421,74 64,90 
 
     
The most effective was the fourth pool of imunne serum 
to the IΙΙ isoform. In its presence 60% of infected mace 
survived, and on the 14th post- infection day in the blood 
serum and in the lungs, we did not detect either 
hemagglutinin, no infectious virus. Imunne serum to 
isoform VI did not protect mice from death, although 
isoform IΙΙ differed from isoform VI by only one protein 
with  molecular mass 32 kDa [18].  
     
 
Table 3 Influence of antiproteinase immune sera on survival of mice under infection with lethal dose of influenza virus 
A/PR/8/34 
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0 0 0 0 
2 I II 2/1
0 
2/1
0 
 4/1
0 
        2 20 
3 II III   2/1
0 
  2/1
0 
 2/1
0 
  2/10  2 20 
4 III IV      2/1
0 
  2/1
0 
   6 60 
5 IV V   2/1
0 
 2/1
0 
4/1
0 
      2 20 
6 V VI   5/1
0 
3/1
0 
2/1
0 
       0 0 
7 VI VII    7/1
0 
1/1
0 
1/1
0 
      1 10 
6 Sodium chloride 
solution 
 0/1
0 
0/1
0 
0/1
0 
0/1
0 
0/1
0 
0/1
0 
0/1
0 
0/1
0 
0/1
0 
0/1
0 
0/10 0/10 10 100 
7 Serum-free virus    2/1
0 
 2/1
0 
6/1
0 
      All  
died 
 
0 
8 Healthy rats 
serum 
     2/1
0 
3/1
0 
 5/1
0 
    All  
died 
 
0 
9 Immune serum 
IVgr., virus-free 
(toxicity) 
 0/1
0 
0/1
0 
0/1
0 
0/1
0 
0/1
0 
0/1
0 
0/1
0 
0/1
0 
0/1
0 
0/1
0 
0/10 0/10 10 100 
Note: 1. numerator – number of mice dies; 2 – denominator – number of mice in the experiment. 
 
From the lungs of healthy mice, we have isolated an inhibitor of trypsin-like proteases with  molecular mass of 
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47.5 kDa, with a high degree of purity and  small amount 
of impurities.  We have developed and patented the 
method of obtaining and purification of trypsin proteinase 
inhibitor [19]. The inhibitor isolated is similar to the 
α1-proteinase inhibitor of human blood serum (48-55 kDa) 
and egg white trypsin inhibitor (49 kDa), but does not have  
not likeness to  trypsin inhibitor isolated from the lungs of 
cattle (an inhibitor of Northrop-Kunitz type), which had a 
molecular mass of 65 kDa. In the study of its effect on the 
proteolytic activity of trypsin-like proteinase isoforms by 
the test-tube method it has been shown that it inhibited the 
activity of almost all isoforms, except isoforms IV (41,8%) 
and VIII (28.3%). In our studies [20] we used a cellular 
inhibitor to suppress the development of influenza virus in 
chicken embryos. It has been revealed that it inhibited the 
development of infectious and hemagglutinating activity 
and the formation of total protein. At the same time, the 
inhibitor of trypsin-like proteinase isolated from the lungs 
of mice, previously infected with influenza virus, did not 
have this ability. In the further studies [21] for the 
treatment of influenza infection in animals, we used the 
inhibitor, which was isolated from the lungs of healthy 
mice.  
 
 
Figure 2  Changes of proteinase and inhibiting activity in chicken embryos at a big infecting dose of influenza virus A/PR/8/34. AI– 1 unit equals 1 mg crystalline 
trypsin, A– 1 unit activity  equals 1 mkg arginin / min. 
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 The introduction of this inhibitor to mice previously 
infected with a lethal dose of influenza virus reduced the 
death rate from this disease due to inhibition of HA 
splitting on reproduction of the virus in the lungs, stopping 
the generalization of the process, preventing the increase of 
proteolysis in the lungs, as well as preventing aerohematic 
barrier and improved some of the reactions of local 
protection.  
 For an antiviral drug preparation that has the lowest 
allergic action on humans, we used  wastes of donor blood 
which is taken for isolation of gamma - globulin and 
albumin.  
At the first stage of  γ-globulin and albumin 
manufacture  from  fraction   (II +III,   by Cohn E.J. ) 
fibrinogen is precipitated, which is later recycled. 
According to our data, the wastes contain 481.11 mg of 
trypsin-like proteinase inhibitor per kg of weight. This 
centrifugate contained α1 - antitrypsin, which is the main 
inhibitor of serine proteases of human blood plasma. Its 
share in the norm is 90% of antitripsin activity of human 
blood plasma [22].  
     In the second step of γ-globulin obtaining, 
precipitate containing prothrombin, α-and β-globulins and 
lipoids is utilized. This precipitate, according to our data 
[23], contains 469.87 mg of trypsin proteinase inhibitor per 
kg of mass. Antithrombin-3 (AT-3) or heparin factor - a 
regulator of blood coagulation is included in this sediment. 
According to O.A Markova et al. [24], normally the content 
of AT-3 in donors ranged from 160 to 250 mcgr / ml. 
α1-antitrypsin and α2-macroglobulin [24, 25] are also in 
the area of α-globulins [24, 25]. 
 
Table 4 Action of cellular inhibitor of trypsin-like proteinase of the survival rate of mice infected with lethal dose of 
influenza virus А/PR/8/34 
N and name of 
 group  
Number 
of animals 
Dose of 
influenza 
virus 
Dose of 
inhibitor on 
mice per 
protein 
Number of animals % of animals 
protected from 
virus Dies Survived 
1. Influenza virus 40 10-3 - 40 - 0 
2. Influenza virus 
+trypsin, crystal. 
40 10-3 18 mkg 40 - 0 
3. Influenza virus + 
inhibitor from healthy 
lungs 
40 10-3 18 mkg 7 33 82,5 
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4. Cellular inhibitor 40 10-3 18 mkg - 40 100 
5. Trypsin, crystal 10 - 18 mkg - 10 100 
6.Phosphate buffer 10 
 
- 0,2 ml - 10 
 
100 
 
 
 In the third stage of γ-globulin obtaining the sediment 
containing plasminogen  goes to waste. At this stage 
wastes, according to our data, the content of trypsin 
proteinase inhibitor was 137.40 mg/kg.  
 At the fourth stage at γ-globulin sedimentation 
centrifugate N 3 is utilized. According to our records, the 
material of centrifuged № 3 contains 166.37 mg of trypsin 
– like proteinase inhibitor.  
 Thus, the waste product of the first and second stages 
of the technological process in which sediment (II +III)  is 
washing and the allocation of prothrombin takes place may 
serve as the raw material for producing an inhibitor of 
trypsin-like proteinases. These wastes contained the highest 
number of trypsin-like proteinase inhibitor.  
To separate trypsin-like proteinase inhibitor we used the 
wastes of the Ith stage (II + III) of  γ - globulin receipt 
from donor blood, which contained a significant amount of 
this inhibitor. We isolated trypsin-like proteinase inhibitor 
from the centrifugate (wastes) of fraction (II + III) of the 
first stage of the γ-globulin by ion-exchange 
chromatography on DEAE-cellulose-53 (Watman, USA).  
This method allowed to obtain five isoforms with 
inhibitory activity. The first two isoforms, in which there 
was a high content of trypsin-like proteinase inhibitors, 
have been eluted from ion-exchange column with 0.1 M 
phosphate buffer, pH 7.5. The next three isoforms 
containing trypsin-like proteinase inhibitor have been  
eluted by stepwise NaCl gradient of different molarity: the 
third isoform - 0.1 M NaCl, the fourth isoform - 0.2 M 
NaCl, the fifth isoform - 0.5 M NaCl. The volumes of 
isoforms eluates were, respectively: Ist - 35 ml, IInd-195ml, 
IIIrd - 340 ml, IVth - 440 ml, Vth - 605ml. 
The highest content of trypsin-like proteinase inhibitor 
has been registered in the fractions of the Vth isoform, 
which was  the last  eluted from the column 0.5 M NaCl, 
while the lowest content was in the IVth and IIInd isoforms 
eluted from the column 0,2 and 0,1 M NaCl, respectively.  
 Trypsin-like proteinase plays a key role in the 
development of pathological process in an organism. It 
splits the outer protein of the influenza virus - 
hemagglutinin into two subunits: HA1 and HA2. Only after 
the splitting of hemagglutinin with this protease, the virus 
enters the cell and begins to multiply. Inhibitors block the 
process of cleavage of viral proteins by inhibiting the 
activity of cellular enzymes.  
 The viral progeny with non-split, functionally 
non-active viral proteins is formed in the presence of 
inhibitors of cellular trypsin-like proteinases after a single 
reproduction cycle of the primary virus with split proteins. 
Subsidiaries virions are not able to initiate the infectious 
process because of the block of the early stages of the 
reproduction cycle - adsorption and penetration of the virus 
[26, 27].  
 To study the protective action of trypsin-like proteinase 
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inhibitor on the survival of mice infected with the lethal 
dose of influenza virus A/PR/8/34, we took 90 white mice 
of BALB/c line weighting 16-18 g and the fifth isoform of 
proteinase inhibitor isolated from the wastes of the first 
stage of γ- globulin production, as it had the highest 
indexes of  the inhibitor activity  (132.52 g / l) and the 
lowest indexes of trypsin-like proteinase (0.0027 mmol in 
the sample). 
 The mice were divided into 7 groups containing  15 
items in each, with 10 items in control groups (Tab. 4). The 
animals of the first group received lethal dose of virus 
(virus control). The virus was administered intranasally in a 
volume of 0.05 ml under Rausch anesthesia. The second 
group of animals got a similar dose of virus, but they were 
treated with crystalline trypsin (control of medical 
properties of crystalline trypsin) in the same doses and 
terms as the animals of the 3rd group.  
The third group of animals was infected with the same 
dose of virus and was treated with trypsin – like proteinase 
inhibitor obtained from the wastes of γ-globulin.  
 The fourth group of animals got only an inhibitor of 
proteinases from the wastes of γ-globulin production 
(control inhibitor’s toxicity).  
 Crystalline trypsin (trypsin control) alone was 
introduced to the animals of the fifth group, the sixth group 
got phosphate buffer, with which we diluted virus inhibitor 
and trypsin. The seventh group was used as the control of 
intact animals. Both trypsin and inhibitor was administered 
intranasally under light ether anesthesia during seven days. 
Each mouse got up to 140 mcg of the inhibitor for the 
course of treatment.  
 The results of our studies showed that the animals of 
the first and second groups died on the 6-7 post-infection 
day. In the third group 12 mice survived (80%). They 
remained alive for 14 days after infection (observation 
period). Animals of the 4th, 5th, 6th and 7th groups 
remained alive throughout the whole period of observation. 
In addition, newly acquired inhibitor of trypsin-like 
proteinases, did not cause toxicity, as white mice of the 4th 
group remained alive at the 14th day after introducing of 
the inhibitor. 
Thus, the findings of our work indicate that trypsin-like 
proteinase inhibitor obtained from the wastes of the first 
stage of  γ – globulin production possessed antiviral 
properties. It is not excluded that it can be used not only for 
influenza treatment but for the treatment of other viral 
infections in which the splitting of  viral precursor protein  
is produced by cellular tripsin-like proteinases [21].  
 
 
Conclusion 
 
  One of the most important stages of the development of 
many viruses in the host organism is their introduction into 
the cell after preliminary deproteinization. Regulation of 
this cycle by proteolytic enzymes of the host-cell is one of 
the fundamental principles of viral reproduction. Induction 
or introduction of inhibitor of the virus proteolytic 
activation is one of the promising ways of viral diseases 
treatment, including influenza. 
  Inhibitor of trypsin-like proteinases obtained from 
industrial wastes of γ-globulin manufacture blocked the 
development of grippe infection in white mice preliminary 
infected with lethal dose of influenza virus  A/PR/8/34 
(A/H1N1). 
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